Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Werewolf Therapeutics stock

Learn how to easily invest in Werewolf Therapeutics stock.

Werewolf Therapeutics Inc is a biotechnology business based in the US. Werewolf Therapeutics shares (HOWL) are listed on the NASDAQ and all prices are listed in US Dollars. Werewolf Therapeutics employs 47 staff and has a trailing 12-month revenue of around $4.1 million.

How to buy shares in Werewolf Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – HOWL – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Werewolf Therapeutics stock price (NASDAQ: HOWL)

Use our graph to track the performance of HOWL stocks over time.

Werewolf Therapeutics shares at a glance

Information last updated 2022-09-22.
Latest market close$4.83
52-week range$3.42 - $18.22
50-day moving average $5.63
200-day moving average $6.35
Wall St. target price$16.50
PE ratio 0.9381
Dividend yield $0 (0%)
Earnings per share (TTM) $5.65

Buy Werewolf Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 7 of 7
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, ETFs, Cryptocurrency
$0
$0
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
eToro
Stocks, ETFs, Cryptocurrency
$0
$10
8%-12% of your deposit
when you sign up and deposit at least $50. T&Cs apply.
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, TN, and HI.
Public
Stocks, ETFs, Cryptocurrency
$0
$0
Receive a free stock slice worth between $3–$300
when you sign up for an account and deposit at least $20.
Commission-free trading in stocks and ETFs with a social networking twist.
Tastyworks
Stocks, Options, ETFs, Cryptocurrency
$0
$0
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0
$0
$125 - $625
when you open and fund an account with $25,000 - $250,000+
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 3% interest on uninvested cash in your account with Robinhood Gold.
Tradier
Stocks, Options, ETFs
$0
$0
N/A
Customize your trade platform or build your own Deep tools, charts and screens Analyzers to help you study before you trade
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Werewolf Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Werewolf Therapeutics price performance over time

Historical closes compared with the close of $4.83 from 2022-09-29

1 week (2022-09-23) -3.78%
1 month (2022-09-01) -20.17%
3 months (2022-07-01) 16.67%
6 months (2022-04-01) 7.33%
1 year (2021-10-01) -72.00%
2 years (2020-09-27) N/A
3 years (2019-09-27) N/A
5 years (2017-09-27) N/A

Is Werewolf Therapeutics stock undervalued or overvalued?

Valuing Werewolf Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Werewolf Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Werewolf Therapeutics's P/E ratio

Werewolf Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 1x. In other words, Werewolf Therapeutics shares trade at around 1x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

However, Werewolf Therapeutics's P/E ratio is best considered in relation to those of others within the biotechnology industry or those of similar companies.

    Werewolf Therapeutics financials

    Revenue TTM $4.1 million
    Gross profit TTM $0
    Return on assets TTM -21.2%
    Return on equity TTM -39.54%
    Profit margin 0%
    Book value $4.56
    Market capitalisation $156.5 million

    TTM: trailing 12 months

    Werewolf Therapeutics share dividends

    We're not expecting Werewolf Therapeutics to pay a dividend over the next 12 months.

    Werewolf Therapeutics overview

    Werewolf Therapeutics, Inc. , a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. The company is also developing WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

    Frequently asked questions

    What percentage of Werewolf Therapeutics is owned by insiders or institutions?
    Currently 19.206% of Werewolf Therapeutics shares are held by insiders and 73.867% by institutions.
    How many people work for Werewolf Therapeutics?
    Latest data suggests 47 work at Werewolf Therapeutics.
    When does the fiscal year end for Werewolf Therapeutics?
    Werewolf Therapeutics's fiscal year ends in December.
    Where is Werewolf Therapeutics based?
    Werewolf Therapeutics's address is: 1030 Massachusetts Avenue, Cambridge, MA, United States, 02138
    What is Werewolf Therapeutics's ISIN number?
    Werewolf Therapeutics's international securities identification number is: US95075A1079

    More guides on Finder

    Ask an Expert

    You are about to post a question on finder.com:

    • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
    • finder.com is a financial comparison and information service, not a bank or product provider
    • We cannot provide you with personal advice or recommendations
    • Your answer might already be waiting – check previous questions below to see if yours has already been asked

    Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

    By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

    Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
    Go to site